1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions

Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions

  • June 2014
  • -
  • Industry Standard Research
  • -
  • 31 pages

This report features survey data portraying the perspectives of US physicians (cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists) regarding their familiarity and prescription propensity for biosimilar products. This is not ISR’s first report on the views that US physicians hold regarding biosimilars. In comparison to our 2013 Biosimilar Primer report, physician familiarity with biosimilars has increased. With this data, biopharmaceutical companies, payers, and service providers can make more informed decisions regarding product marketing, delivery, and manufacturing.

Table Of Contents

Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions
Copyright and usage guidelines 3
Introduction 4
Methodology 7
Data collection 7
Sample source 7
Respondents 7
Practice type 7
Definition given to respondents 7
Executive summary 9
Familiarity 9
Prescribing likelihood 9
Pricing 9
DAW clause 9
Clinical development 10
Familiarity with biosimilars 11
Biosimilar familiarity 12
Prescribing and pricing 13
Medicine identification 14
Likelihood of prescribing a recently approved biosimilar 15
Discount required for physician recommendation 16
Switching and DAW preference 17
Importance of being notified of pharmacist decision to dispense alternative biologic … 18
Opinion on EU ban on pharmacy-level substitution 19
Percent of expected biologic prescriptions to be written with a DAW clause 20
Likelihood to use DAW clause 21
Preferred clinical testing for biosimilars 22
More concerned about safety or efficacy 23
Demographics 24
Job position 25
Practice type 26
Medical specialty 27
Board certified 27
Years in practice 28
Patients per week 28
Number of physicians at practice 28
Number of PAs at practice 28
Number of NPs at practice 28
Office location by State 29
Practice setting 30
About Industry Standard Research 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.